Yes, Lupron (leuprolide acetate) is FDA-approved for both prostate cancer and endometriosis.
How Lupron treats prostate cancer
Lupron is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone production, slowing prostate cancer growth in advanced cases. It's used for palliative treatment of metastatic prostate cancer and as adjuvant therapy with radiation for localized disease.[1][2]
How Lupron treats endometriosis
For endometriosis, Lupron reduces estrogen levels, shrinking endometrial implants and easing symptoms like pelvic pain. It's approved for short-term use (up to 6 months) in women, often before surgery or when other treatments fail.[1][3]
Key differences in use and dosing
Prostate cancer dosing is typically 7.5 mg monthly, 22.5 mg every 3 months, or longer-acting depot forms up to 6 months. Endometriosis uses lower doses like 3.75 mg monthly for up to 6 months, with add-back therapy (low-dose hormones) to reduce bone loss risks.[1][4] Men tolerate longer durations better due to different side effect profiles.
Common side effects across both conditions
Hot flashes, fatigue, decreased libido, and bone density loss occur in both. Prostate patients may see testosterone flare initially; endometriosis patients face menopausal symptoms like vaginal dryness.[1][2][3]
When doctors choose Lupron over alternatives
For prostate cancer, it's often first-line hormone therapy versus orchiectomy or antagonists like degarelix. In endometriosis, it's for moderate-severe cases unresponsive to NSAIDs or birth control, but not first-line due to side effects.[4]
[1]: FDA Label for Lupron Depot
[2]: American Cancer Society on Hormone Therapy
[3]: FDA Label for Lupron 3.75 mg
[4]: UpToDate: GnRH Agonists for Endometriosis